Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
Enzyme Activity Assays in Rare Disease Drug Programs: Design, Validation, and Interpretation Across Four Clinical Contexts
A single enzyme activity assay format cannot equally serve diagnosis, pharmacokinetics, pharmacodynamics, and gene therapy efficacy readouts in lysosomal storage disorder programs. A 2026 review in Bioanalysis and supporting primary literature clarify how assay purpose, matrix, and immunogenicity monitoring must be aligned before validation begins. This article is for Research Use Only.
Platform Choice at the Core of ADC Bioanalysis: What the Gyrolab-vs-Plate Debate Actually Requires Scientists to Decide
Selecting between Gyrolab microfluidic and conventional plate-based immunoassay platforms for antibody-drug conjugate bioanalysis is not a single decision but a structured one made analyte by analyte. A sponsored interview published October 13, 2026, on Bioanalysis Zone, combined with the July 2026 AAPS ADC Working Group white paper in AAPS Journal, provides the clearest current framework for making those choices across total antibody, conjugated antibody, free payload, and immunogenicity assays. All assay content discussed is for Research Use Only.
When PK Studies Slim Down, Immunogenicity Assays Carry More Weight: What FDA's 2026 Biosimilar Guidance Means for Bioanalytical Scientists
FDA's March 2026 draft guidance removes the default requirement for comparative PK bridging studies in biosimilar development, building on a prior October 2025 draft that proposed eliminating routine efficacy trials. Both actions shift evidentiary weight onto immunogenicity assays, raising the bar for ADA assay design, drug tolerance, and neutralizing antibody assessment before any clinical samples are collected.